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Research in Context 
Evidence before this study 
In November 2017, the Lancet Neurology Commission on Traumatic Brain Injury (TBI) highlighted 
existing deficiencies in epidemiology, patient characterization, identifying best practice, outcome 
assessment, and evidence generation.  The Commission concluded that  “ŽŶĐĞƌƚĞĚĞĨĨŽƌƚƐĂƌĞƵƌŐĞŶƚůǇ
needed to address deficiencies in prevention ?ĐĂƌĞĂŶĚƌĞƐĞĂƌĐŚ ?, and made a recommendation for 
large collaborative studies which could provide the framework for precision medicine and comparative 
effectiveness research (CER). 
Added value of this study 
The CENTER-TBI Registry and Core Study provide detailed insights into the contemporary landscape of 
TBI in Europe and constitute a unique resource for improving characterization, developing precision 
medicine approaches and identification of best practices. The epidemiology of TBI presenting to 
European centres is changing: patients are older, have most commonly been injured by a fall, and many 
have comorbidities. Advanced neuroimaging and blood biomarkers can improve characterisation of 
injury type and severity.  Differentiation of patients by care pathways provided novel insights. Around 
95% of patients discharged from the Emergency Room or admitted to the ward, and a third of those 
primarily admitted to the ICU, have suffered a so-ĐĂůůĞĚ “ŵŝůĚd/ ? ?,ŽǁĞǀĞƌ ?ŶĞĂƌůǇŽŶĞƚŚŝƌĚŽĨƚŚŽƐĞ
discharged from the ER and over half of those admitted to hospital ward did not attain full recovery. 
There are substantial national and regional variations in care pathways and clinical management. 
Implications of all the available evidence: 
TBI should no longer be considered predominantly a disease of otherwise healthy young adult males. 
Falls are the most common cause of TBI and motivate an increased focus for prevention. Mild TBI not 
only poses the greatest societal burden to health care, but also impacts functional recovery and quality 
of life in individuals more than commonly thought. Better disease characterisation can contribute to 
precision medicine approaches through the development of multidimensional classifications of initial 
injury severity and outcome.  Variations in care offer an opportunity for CER to identify best practice.  
 
 
 
  
Abstract  
Background 
Traumatic Brain Injury (TBI) poses a large public health and societal problem, but the contemporary 
landscape in Europe is poorly defined. We aimed to characterize patient case-mix, care pathways, and 
outcome of TBI. 
 
Methods  
CENTER-TBI is a Europe-based observational cohort study, consisting of a Core study (Inclusion criteria:  
clinical diagnosis of TBI, presentation <24 hours post-injury and indication for computed tomography) 
and a Registry. Patients were differentiated by care pathway: ER stratum (discharged from emergency 
room), Admission stratum (hospital ward), and ICU stratum (admission to the intensive care unit). 
Neuro-images and biospecimens were stored in repositories and outcome assessed 6 months post-
injury. 
 
Findings 
Data of 4509 patients from 18 countries were analysed in the Core study and 22,782 in the Registry. In 
the Core study, 848 (19%), 1523 (34%), and 2138 (47%), were in ER, Admission, and ICU strata, 
respectively. In the ICU stratum, 36% of patients had mild TBI (Glasgow Coma Score 13-15). Compared 
to the Core cohort, the Registry had more patients in ER (43%) and Admission (38%) strata, with >95% 
classified as mild TBI. Patients in the Core cohort were older than past studies (median age 50 [IQR: 30-
66] years, 28% >65 years), 11% had serious comorbidities, 18% were taking anticoagulant or antiplatelet 
medication, and alcohol was contributory in 25%. Magnetic resonance imaging (MRI) and blood 
biomarker measurement enhanced characterisation of injury severity and type. Preliminary MR analyses 
showed abnormalities in 60 (30%) of 202 patients with normal CT scans. Substantial inter-country 
differences existed in care pathways and practice. Incomplete recovery (Glasgow Outcome Scale 
Extended [GOSE] <8) was found in 30%, 53%, and 84% of patients in the ER, Admission and ICU strata 
respectively. In ICU patients with moderate to severe TBI, the rate of unfavourable outcome (GOSE<5) 
was 55%, similar to that predicted by the IMPACT prognostic model (O/E ratio 1·06 [95% CI 0·97-1·14]), 
but mortality was lower than expected (O/E ratio 0·70 [95% CI 0·62-0·76]).  
 
Interpretation  
Compared to past studies, many patients with TBI currently presenting to European centres are older 
and have comorbidities. Overall, patients most commonly present with mild TBI, and often experience 
incomplete recovery. Precision medicine and identification of best practices with comparative 
effectiveness research hold promise to improve these outcomes.   
 
Key Words: Traumatic Brain Injury, biomarkers, comparative effectiveness research, epidemiology, 
neuro-imaging, outcome, precision medicine,  prospective observational study 
 
Introduction 
 
Traumatic Brain Injury (TBI) is widely recognized as a large public health and societal problem.  TBI 
results in 1·5 million hospital admissions and 57,000 deaths in the EU each year,1 but the current 
landscape of TBI in European hospitals is poorly characterized. In 2017, a Lancet Neurology Commission 
on TBI highlighted the burden posed by TBI to patients, relatives, and society, and provided 
recommendations to improve patient outcomes through better prevention, clinical care, and research.2 
One recommendation was for large collaborative observational studies to collect longitudinal data, 
which could inform improved patient characterization to allow better targeting of therapies, and 
identify best practices through comparative effectiveness research (CER).  
The CENTER-TBI project (Collaborative European NeuroTrauma Effectiveness Research: www.center-
tbi.eu) is a collaborative European study, conducted within the InTBIR Initiative (https://intbir.nih.gov/),3 
that was designed to address these needs.4 It includes a multicentre, longitudinal, prospective, 
observational cohort study (Core study) with highly granular data collection and a Registry, collecting 
basic administrative data. The main aims are to 1) better characterize Traumatic Brain Injury (TBI) as a 
disease and describe it in a European context, and 2) identify the most effective clinical interventions for 
managing TBI. Provider Profiles of participating centres were established to characterize structures and 
processes of care in preparation for comparative effectiveness research.5-10 We here aim to describe the 
contemporary landscape of TBI in Europe, with a focus on the patient case-mix, care pathways, and 
outcome in the Core study, and to explore generalizability by comparison to the Registry. 
 
 
Methods 
Study design 
CENTER-TBI includes a Core study (clinicaltrials.gov NCT02210221) and a Registry (RRID: SCR_015582).4 
Of 92 candidate centres, 65 initiated patient enrolment (Figure 1). The Core study is a prospective 
observational longitudinal cohort study on patients of all severities of TBI, presenting between 
December 19, 2014 and December 17, 2017, to centres across Europe and Israel. Inclusion criteria were 
a clinical diagnosis of TBI, indication for CT scanning, presentation to study centre within 24 hours of 
injury, and informed consent obtained according to local and national requirements.4 The only exclusion 
criterion was severe pre-existing neurological disorder that could confound outcome assessments. 
Patients were differentiated by care path into three strata:  
1. ER stratum (patients evaluated in the emergency room (ER) and discharged);  
2. Admission stratum (admitted to hospital ward);  
3. ICU stratum (primary admission to the intensive care unit).  
The assignment to a stratum was prospective in the Core study, and retrospective in the Registry.  
Generalizability of the Core study was assessed through comparison with the Registry, which collected 
administrative data not requiring consent, and covered a site-specific, convenience-based, time window 
during the recruitment period of the Core study. 
 
Informed Consent and data de-identification 
Consent procedures adhered to local and national requirements. Informed consent was preferred, but 
seldom possible as most patients were rendered mentally incapacitated by their TBI. Efforts were made 
to identify a legally acceptable representative (e.g. consultee/proxy). Other options included deferred 
consent and waiver of consent. We specifically sought consent for blood sampling, DNA analyses, and 
sharing data with other researchers (both within and outside of Europe). Subjects were free to 
withdraw, or to be withdrawn by their consultee/proxy: options included complete withdrawal (deletion 
of all data and destruction of biosamples) and partial withdrawal (cessation of new data accrual, but 
permission to use data and biosamples already collected). Locally collected data were de-identified and 
patients allocated a randomly generated GUPI (Global Unique Patient Identifier). All date and time 
entries were zeroed to the Unix epoch, thus permitting analysis of time intervals while preserving de-
identification. Potential patient identifiers were removed from free text, both manually and by 
automated procedures. Images were defaced upon upload. 
 
Core clinical data 
Detailed clinical data were collected using a web-based electronic case report form (eCRF), with 
stratum-specific work flows (QuesGen Systems Incorporated, Burlingame, CA, USA). These included pre-
injury factors, injury details, pre-hospital care, hospital laboratory results, clinical care, post-acute care, 
and outcome. Variables were coded in accordance with the Common Data Elements (CDE) scheme 
established by the National Institutes of Health - National Institute of Neurological Disorders and Stroke 
(NIH-NINDS; https://commondataelements.ninds.nih.gov/). Blood samples and images were obtained 
according to protocol.4 
 
Biobank 
The CENTER-TBI biobank (Pecs, Hungary) stored samples of whole blood, serum and plasma for genetic, 
biomarker and haemostasis analyses, respectively, for both the current study and legacy research.4 
Biomarker analysis was staged: we report on admission samples from 961 patients to explore the 
potential utility of candidate biomarkers, which included Neuron Specific Enolase (NSE), S-100B , 
Neurofilament light (NF-L), total tau, glial fibrillary acidic protein (GFAP), and ubiquitin carboxyl-terminal 
hydrolase L1 (UCH-L1).  
 
Neuro-imaging repository  
CT scans were obtained in all patients upon presentation. Follow up CT scans were acquired as clinically 
indicated  or by local protocol.4 MR scans were obtained in a subset of participating centres, and results 
are provided on analysis of the first 504 early (<3 weeks) studies. Images were scored locally, details 
captured in the e-CRF, and subsequently uploaded into a central repository coordinated and maintained 
by Icometrix (https://icometrix.com/). All uploaded images were read centrally using NINDS CDE-based 
structured qualitative reporting 
(https://www.commondataelements.ninds.nih.gov/Doc/SharedForms/F0328_Imaging.docx). 
 
Outcome data 
Outcome assessments included health-related quality of life, psychosocial and symptom questionnaires 
and neuropsychological testing. Questionnaires were translated into national languages and 
linguistically validated.4 Telephone or postal interviews were permitted in addition to face-to-face 
assessments. Cross-sectional outcome assessments across all strata were performed at 6 months post-
injury. We report on the three primary outcome measures as defined on registration of the study 
(functional outcome: GOSE;11 and health-related quality of life: Qolibri-OS12 and SF-12v2),13 and on 
mortality at 6 months after injury. We classified Qolibri-OS scores <52 and SF-12v2 summary scores < 40 
as impaired.14 
 
Data handling and curation 
Data were stored on a secure database, hosted by the International Neuroinformatics Coordinating 
Facility (INCF; www.incf.org) in Stockholm, Sweden. Source data verification of major characteristics was 
undertaken on a quasi-random sample of 1298 patients (28%) by a designated Contract Research 
Organization (ICON, Ltd, Paris). A multidisciplinary data curation task force addressed data missingness 
and plausibility, tested for multivariate consistency by cross-checking variables, and calculated derived 
variables to aid analyses. The cleaned and fully de-identified database was accompanied by a data 
dictionary with detailed descriptions of data manipulation or transformation applied, and an explicit 
record of non-resolvable curation issues. A data management tool,  ‘EĞƵƌŽďŽƚ ? 
(http://neurobot.incf.org) was developed by INCF (RRID: SCR_01700). This facilitated data extractions, 
with the script storable as a unified resource locator for subsequent reuse, reference, or sharing. 
Imaging files and high-resolution data were stored in separate repositories.15  
 
Data analysis  
For the current analysis we used Neurobot vs 1.1 (data freeze: January 2019). We report median and 
interquartile ranges (IQR) for continuous or ordinal variables, and numbers and percentages for 
categorical variables. All analyses were differentiated by stratum and performed in R statistical software 
(3.5.1) and RStudio (1.0.136). Analysis of variance (ANOVA) was used for comparison of continuous 
variables across strata. The chi-square test was used for comparison of categorical variables. Kappa 
statistics were used to express the agreement between central and local radiological evaluation of 
admission CT scans and for CT versus MR scans.  
 
Patients without any GOSE assessment were excluded from analysis (n=705; 16%). The 6-month GOSE 
scores were available within the 5-8 month protocol window for 2186 (62%) patients. For 988 patients 
(22%) with scores outside the 5-8 month window, we used a multistate model to impute the 180-day 
GOSE (msm R package).16 We used the IMPACT Core model for the expected mortality and proportion 
with unfavourable GOSE outcome among patients with moderate or severe TBI (Glasgow Coma Score <= 
12).17 Observed mortality and unfavourable GOSE outcomes were compared to expected outcomes and 
expressed as a ratio with 95% confidence intervals estimated according to a Poisson distribution. 
For calculating SF-12v2 summary scores, we used the SF-12v2 questionnaires where completed, 
supplemented by derived scores using SF-36v2 items when available.  
 
Role of funding source: 
The funders had no role in the collection, analysis and interpretation of data, nor in the writing of the 
report or in publication decisions. The authors had full access to study data and the senior authors had 
final responsibility for the decision to publish. 
 
Results  
Data collection 
The Core study enrolled 4,559 patients and the Registry 22,849 from 65 sites in 19 countries. Of these, 
data from 4509 patients in the Core study and 22782 in the Registry were analysed (Figure 1). The 
median enrolment by centre in the Core Study was 50 patients (IQR: 21-107), with widely different 
distributions across strata (Figures 2 and S1). In the Core study, 848 (19%), 1523 (34%), and 2138 (47%), 
were in ER, admission and ICU strata respectively. Compared to the Core study, the Registry enrolled 
more patients in the ER (9839, 43%) and Admission strata (8571, 38%) (Figure 1).  
Baseline and Injury characteristics of Core cohort (Table 1) 
Overall, the median age was 50 (IQR: 30 W66) years, with 28% >65 years of age. Patients in the Admission 
stratum were older (53 years, 32% >65), compared to those in the ER and ICU strata. Male patients were 
overrepresented in every stratum, most notably in the ICU stratum (73%). At higher age, however, the 
proportion of females was higher in the ER and Admission strata (Figure 3). Mild or severe systemic 
disease was reported in 43%. 
Differences were noted in patient characteristics between the three strata with respect to socio-
economic characteristics (education, marital and employment status), medical history (especially 
frequency of having had a previous TBI), cause of injury and clinical severity (Tables 1, S1 to S4). An 
incidental fall was the most common cause of injury in the ER and Admission strata (51% in both). A 
clear association with age was noted, with high rates of falls occurring in those < 10 years of age and in 
the elderly (>65 years, Figure S2). Road traffic incidents were more common in the ICU stratum (45%). 
Alcohol use was reported in 64% of all violence-related TBI, in 28% of incidental falls and in 17% of road 
traffic incidents (Figure S3). Recreational and prescription drug use were reported in 5·7% of patients.  
Clinical severity varied by stratum: In the ER and Admission strata, the median baseline Glasgow Coma 
Score (GCS) was 15 and 99% and 93% respectively were classified as mild TBI (GCS 13-15) (Table 1, 
Figure 4). In the ICU stratum, the median GCS was 9 and 36% of patients had a GCS>12. Major 
extracranial injuries (AIS>=3) were reported in 27% of patients in the Admission stratum and in 55% of 
those in the ICU stratum. The body region most commonly injured was thorax/chest (35%), whilst 
concomitant serious spinal injuries occurred in 18% (Table S4). 
Comparisons with Registry 
The differential recruitment to individual strata in the Core study and the Registry (Figure 1), and the 
exclusion of patients with pre-existing neurological disease from the Core cohort, precluded overall 
comparison between the two cohorts. When differentiated by stratum, patients in the Core study 
broadly resembled those in the Registry (Table S5): Similar proportions had serious extracranial injuries 
(27% vs 28% in the admission cohorts, and 55% vs 53% in the ICU cohorts respectively), and similar 
proportions of patients in the ICU strata arrived intubated at the ER (44% in Core and 41% in Registry) . 
In the ICU strata, the frequency of emergency surgical procedures was similar (e.g. craniotomy for 
haematoma/contusion 14 vs 16%, respectively. In-hospital mortality was similar across strata (e.g. 15% 
and 19% for the ICU stratum in Core and Registry, respectively). Some differences existed in other 
baseline and injury characteristics (Table S5): Patients in the Core ER stratum were more frequently 
injured in road traffic incidents (32% vs 24%) and had more intracranial abnormalities on CT scanning 
(15% vs 5·1%) than their Registry counterparts. Patients in Core admission stratum were younger (53 vs 
64 years), more often male (65 vs 60%), more frequently injured in road traffic incidents (33% vs 25%) 
and had more intracranial abnormalities on CT scanning (49% vs 36%). The Core ICU stratum enrolled 
patients with a lower baseline GCS (median 9 vs 12, Table S5). 
CENTER-TBI Neuro-imaging repository and biobank 
Early CT scans showed traumatic intracranial abnormalities in 2434 of 4037 (60%) at central review: 
15%, 49%, and 89% in the ER (n=127), admission (n=680) and ICU (n=1627) strata, respectively (Table 1, 
Table S6). The most frequently reported abnormalities were traumatic subarachnoid haemorrhage 
(1843, 46%) contusion (1325, 33%) and an acute subdural hematoma (1241, 31%; Table S6). 
Comparisons between central review scores and investigator scores showed good agreement for 3922 
initial CT scans (kappa 0·79 for any abnormality, Table S7). Relatively low kappa values were found for 
traumatic axonal injury (0·35) and cisternal compression (0·54).  An early MRI (<3 weeks) showed 
traumatic intracranial abnormalities in 312 of 504 patients (62%; Table 1). Abnormalities on MR were 
noted in 60/202 (30%) with a normal admission CT scan (Table S8). Conversely, MR imaging was normal 
in 32/182 (18%) patients with traumatic abnormalities on the CT scan obtained at presentation. MRI 
showed more contusions (32% vs 22%) and traumatic axonal injuries (35%  vs 5%), but  CT detected 
more subarachnoid hemorrhage (32% vs 23%) and epidural hematoma (9% vs 6%, Table S8).  
The CENTER-TBI biobank included serum samples from 3833 subjects, whole blood samples from 3649 
patients and plasma samples for haemostasis analyses from 604 subjects. Values for S100B, NSE, GFAP, 
NFL, Total Tau, and UCHL1 were all highest in the ICU stratum (Table 1).  Levels of biomarkers were 
significantly associated with the presence of intracranial injuries at CT scans (Figure S4), and scaled 
inversely with the GCS (Figure S5). The levels of different biomarkers showed close correlations (Figure 
S6). 
Care pathways 
In total, 731 patients (16%) were transferred from another hospital to the study centre, with substantial 
variations in secondary referral rates across countries (Table 2; Figure 5); most secondary transfers 
(24%) occurred in the ICU stratum (Table 2).  Compared to primary referral, secondary referral increased 
the time required to reach definitive treatment at the study centre 5 times (median 65 minutes vs. 295 
minutes; p<0·001). Overall, 591 (62%) patients with a GCS <9 received an ICP monitor (Table 2), but 
there were substantial variations across countries (Figure 5). Intracranial surgery was performed in 885 
(24%), and extracranial surgery in 735 patients (20%, Tables 2 and S9). An acute subdural hematoma 
was the most frequent indication for intracranial surgery (n=323; 25% of all intracranial procedures), 
and an extremity fracture for extracranial surgery (n=457; 35% of all extracranial procedures). 
Decompressive craniectomy was performed in 195 patients (Table S9).  
Of patients initially enrolled in the ER stratum, 37 (4·8%) were admitted to hospital (Figure 6). 
Nevertheless, the vast majority of patients in the ER stratum (99%) could be discharged home (Table 2). 
From the Admission stratum, most patients went home (85%) after a median hospital stay of 2·5 days, 
and 59 (4%) were discharged directly to a rehabilitation centre. For the ICU stratum, ICU mortality was 
13% (n=272), and most patients were initially discharged to the ward (n=1131; 60%), with a median ICU 
length of stay of 6.1 (IQR: 1·9-15) days, and a total inpatient length of stay of 17 (IQR: 7·9 W32) days.  A 
total of 518 (27%) were subsequently transferred to another hospital, some were further treated at a 
rehabilitation centre (n=421, 22%), few went to a nursing home (n=46, 2·4%) (Table 2, Figure 5).  
Outcome 
Some patients in the ER and Admission strata died (3, 0·3% and 42, 2·8%, respectively). The in-hospital 
and 6-month mortality in the ICU stratum was much higher (15% and 21%, Table 3). A 6-month GOSE 
score was available for 3804 patients (87%, Table 3, Figure 7). Death or severe disability occurred in 43% 
of patients in the ICU stratum. A GOSE < 8 was observed in 84% of patients in the ICU stratum, in 53% of 
the Admission stratum, and in 30% of the ER stratum (Table 3). This failure to achieve a complete 
functional recovery was also reflected in quality of life scores: rates of Qolibri-OS of <52 in survivors 
were 25%, 18%, and 19% in the ICU, Admission and ER strata, respectively. SF-12v2 scores showed 
similar results (Table 3). A comparison of baseline characteristics between patients with and without 
available outcome showed that those with missing outcome were generally younger, less educated, less 
severely injured and that alcohol was more frequently involved (Table S10). 
 
In 1132 patients >14 years with moderate or severe TBI (GCS <=12), all covariates for the IMPACT core 
model and GOSE were available (84% of eligible patients). The observed 6-month mortality was 347 
(30%), while 504 (43%) deaths were expected (O/E ratio 0·70 [95% CI 0·62-0·76]). An unfavourable 
outcome (dichotomised at GOSE<5) was noted in 55%, which was not better than expected (O/E ratio 
1·07 [95% CI 0·97-1·14]). 
Discussion 
This integrated analysis of the CENTER-TBI study describes the landscape of TBI as currently seen in 
European hospitals, which differs substantially from previous observational studies: Patients are 
older, have more co-morbidities, and injuries are most frequently caused by falls. The median age in 
the Core Study is 50, substantially higher than in the UK 4 centre study or the EBIC survey.18-19 
CENTER-TBI is unique in that it covers all severities of TBI and differentiates patients by care pathway 
rather than by the traditional classification of TBI severity by the GCS into mild, moderate or severe. 
The stratification of patients by care pathway demonstrates clear discordances with GCS-based 
classification of TBI severity, reflects care provided, affords new clinical insights, and sets a context 
for comparative effectiveness research (CER). CENTER-TBI highlights the substantial healthcare 
ďƵƌĚĞŶĂŶĚŽƵƚĐŽŵĞŝŵƉĂĐƚŽĨd/ ?ƉĂƌƚŝĐƵůĂƌůǇĨŽƌ “ŵŝůĚ ?d/ ?ĞƐƉŝƚĞĂ median admission GCS of 
15, a quarter of patients in the Core ER stratum and half in the Core Admission stratum were not fully 
recovered at 6 months. The Registry showed that such patients constitute 81% of all patients 
presenting with TBI, suggesting that while severe TBI may be devastating for individuals, mild TBI 
poses the greatest burden to health systems ?&ŽƌƐŽŵĞŝŶĚŝǀŝĚƵĂůƐ ?ŵŝůĚd/ŵĂǇŶŽƚďĞ “ŵŝůĚ ?ĂƚĂůů ? 
and results in a greater burden of late problems than commonly appreciated. 
 
TBI epidemiology: A changing landscape 
Our study confirms that TBI should no longer be considered predominantly a disease of healthy 
young males.20 Overall, 28% of the population was >65 years of age compared to ~10% in past 
series.21 The most common cause of injury was incidental falls, which increased with age, from 
around 50% in the age group 50-60 to over 75% in patients over age 80 years. These findings 
motivate an increased focus on fall prevention in the elderly. 
 
Co-morbidities were present in 43% of the population, and anticoagulants or platelet aggregation 
inhibitors taken by 18%, reflecting the increasing age and frequent need for treatment of 
cardiovascular comorbidities. The highest incidence of prior anticoagulant or antiplatelet therapy 
was in the admission stratum (21%) and may have predicated the need for a period of observation, 
and driven hospital admission in a substantial subset of patients. Better prediction of the risks of late 
lesion development or progression in these patients might avoid unnecessary admission and result in 
health-economic benefits. 
 
Alcohol was thought to be a contributory factor in a quarter of cases; recreational and prescription 
drug use were contributory factors in  6%.These numbers are broadly in keeping with recent 
reports.22-24 Alcohol was highly prominent in violence-related TBI and involved about twice as often 
in incidental falls compared to RTIs. In public health terms, these findings speak to the need for 
continued efforts to reduce the role of alcohol in injury causation (with an increased focus on fall 
prevention), while being vigilant about the impact of recreational and prescription drugs. 
 
Towards precision medicine approaches 
Conventional characterization of patients with TBI has relied on the GCS and broad categorisation of 
structural damage.25 Our data go beyond these approaches to advance precision medicine in TBI, 
through detailed structured reporting of CT imaging, the inclusion of MRI, and measurement of blood 
biomarkers. The CENTER-TBI neuro-imaging repository and biobank are likely the largest in the world 
on TBI. The NINDS CDE-based structured CT reporting used may be too detailed for routine clinical 
practice, but identification of its essential elements could allow for wider clinical use.  We are 
exploring automated pipelines to provide consistent, objective and accurate detection and 
quantification of imaging covariates,26 which have prognostic relevance and could allow better 
patient stratification. Implementation of harmonized MR imaging in a multicentre international study 
which included non-research imaging centres was demanding, as scanners and software differ and 
units for standardization are lacking. We used phantoms and healthy controls to develop harmonized 
sequences across vendors and machines.27 Our preliminary results show that MRI detected 
abnormalities in 30% of CT negative patients (typically traumatic axonal injury or contusions), and 
frequently uncovered more extensive damage in patients who did show CT abnormalities. The 
increased sensitivity of MRI in this regard (particularly for TAI) is in keeping with past reports.28,29 
However, we also found that MR abnormalities were absent in 18% of CT positive patients, most 
often with tSAH or epidural haematoma.  This may be because later (~2 week) MRI studies may miss 
initial lesions that resolve,30 or because CT is inherently more sensitive at detecting some types of 
injury.  Determining which of these factors is responsible for CT positive-MRI negative imaging is 
critical, since it will inform whether MRI can be safely used as a sole imaging modality in the 
hyperacute stage after TBI. CENTER-TBI has promoted the collection of MRI data within 72 hours of 
injury in a subset of patients, and analyses of this subgroup will permit better quantification of the 
complementary diagnostic and prognostic information provided by these imaging techniques.  
 
We found that biomarker levels scaled with the presence of intracranial abnormalities, TBI severity 
(as defined by GCS), and management path (defined by stratum).  Our data are concordant with 
recent reports,31,32 and motivate further research on the role of biomarkers in identifying the need 
for CT in the patients with least severe injury, selecting CT negative patients for MRI, and 
prognostication in all severities of TBI.  
 
Care pathways and country/centre differences 
We found substantial discordances between conventional stratification of TBI severity (mild, 
moderate, severe) and care pathways. PĂƚŝĞŶƚƐǁŝƚŚ “ŵŝůĚ ?d/ ?'^AN ? ? ?ĐŽŶƐƚŝƚƵƚĞĚĂƚŚŝƌĚŽĨ
patients in the ICU stratum. Plausible explanations  for these admissions to the ICU include advanced 
age, frailty, comorbidities, increased risks of lesion progression due to anticoagulants and antiplatelet 
agents, the need for surgery, and/or extracranial injury.33 Indeed, half of patients in the  ICU stratum 
had significant extracranial injury. Ongoing analyses will address the drivers, costs, and benefits of 
ICU admissions for mild TBI.  
 
We noted significant differences between countries in prehospital care and treatment policies, which 
confirm the findings of the provider profiling questionnaires.5-10 Primary and secondary referrals 
were associated with substantial differences in time to access definitive care,  and the differences we 
observe in secondary referral rates might therefore potentially drive differences in outcomes 
between countries.34  These differences, and  the substantial between-country differences we 
demonstrate in use of ICP monitoring, cranial and extracranial surgery, and ICU and hospital length of 
stay, represent opportunities to use CER to identify best practices. 
 
Outcome 
TBI remains a disease with poor outcomes. Though patients with moderate to severe TBI in the ICU 
stratum showed a greater survival than expected, nearly half experienced unfavourable outcome and 
their functional outcome was no better than expected.  In the ER stratum, 25% of patients had a 
GOSE <8, and hence had not returned to their pre-TBI baseline functioning by 6 months.  These 
functional deficits are also reflected in quality of life measures, and an impaired Qolibri-OS and SF-
12v2 summary scores were seen in  21% (Qolibri-OS), 23% (MCS) and 28% (PCS) respectively of 
survivors.14  These data are sobering, and underline the substantial burden of morbidity for subjects 
who are being discharged from Emergency Rooms, often without follow up, and with no current 
therapeutic options. There is an urgent need to improve outcomes in all patients with TBI, and not 
least in those with supposedly mild TBI. 
 
Generalizability 
Despite broad similarities, we observed some significant differences in terms of case-mix between 
the Core study and Registry. Some of these differences were expected, since recruitment to the Core 
study excluded patients with pre-existing neurological disorders which could have confounded 
assessment of the outcome impact of TBI. This provided a clear reason why patients in the Registry 
(particularly in the Admission stratum) were older and presented more frequently with falls. The 
most notable difference, however, was the lower percentage of patients in the ER stratum in the 
Core study (19%) compared to the Registry (43%). This difference likely reflects research interests of 
participating centres, which are more focussed on more severe injuries, and on the logistic 
challenges for obtaining informed consent in an environment conditioned towards a high turn-over 
rate. Some caution is therefore appropriate when interpreting generalizability of the Core study 
results. 
 
Strengths and limitations 
Particular strengths of CENTER-TBI are the complementary nature of the Core study and the Registry, 
the broad pan-European perspective, the inclusion of all TBI severities and age groups, the focus on 
care pathways, the detailed clinical characterization of patients, and establishment of large neuro-
imaging and biospecimen repositories. Collaboration within the InTBIR initiative will facilitate meta-
analyses across InTBIR studies. It may permit addressing research questions that require larger 
numbers, such as genetic markers in TBI. Several limitations should be acknowledged. We focused 
only on patients presenting to study hospitals and did not include pre-hospital deaths or patients not 
seen in the hospital setting. Second, recruitment to the Core study was not consecutive and 
determined by site logistics and research interests. Third, participating institutions were mainly 
referral centres for neurotrauma, and results may not be completely generalizable to all hospital 
settings. Fourth, we recognize that the paediatric population was under-represented, as participating 
centres mainly focused on care for adults. Fifth, not all data elements were complete. In many of the 
ongoing analyses, multiple imputation will be performed for efficient statistical analyses.35 Similarly, 
while ongoing efforts are steadily increasing rates of recorded outcomes in the dataset, follow-up in 
the current analysis cohort was not complete, although the availability of GOSE outcomes for 86% of 
the enrolled patients compares very favourably to other observational studies. Completion rates of 
other outcome instruments and neuropsychological testing were somewhat lower.  
 
Conclusions 
 CENTER-TBI provides detailed insights into the contemporary landscape of TBI in Europe. TBI should 
no longer be considered predominantly a disease of otherwise healthy young adult males. Mild TBI 
not only poses the greatest societal burden to health care, but also impacts functional recovery and 
quality of life in individuals more than commonly thought. Substantial geographic differences in care 
pathways and treatment approaches exist, which provide a basis for comparative effectiveness 
research to determine best practices. The detailed characterization of patients in the Core study, in 
combination with the neuro-imaging repository and CENTER biobank will contribute to the 
development of multidimensional classifications of initial injury severity and outcome, and to 
precision medicine approaches.   
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Table 1: Characteristics of 4509 patients enrolled in the CENTER-TBI Core study 
Variable N complete N (%) ER (N, %) Admission (N, %) ICU (N, %) p-value *  
Total number of patients  4509 848 1523 2138  
Demographic characteristics 
Age (median (IQR)) 
 
4509 
 
50 (30-66) 
 
48 (29-64) 
 
53 (32-69) 
 
49 (29-65) 
 
0·001 
x >65 years  1254 (28%) 209 (25%) 493 (32%) 552 (26%)  
Male sex 4509 3022 (67%) 473 (56%) 988 (65%) 1561 (73%) <0·001 
Caucasian 4307 4158 (97%) 810 (97%) 1425 (96%) 1896 (97%) 0·33 
 
Socio-economic characteristics 
      
Years of education (median (IQR)) 3212 13 (10  W 16) 13 (11  W 16) 13 (11  W 16)  12 (10  W 15) <0·001 
Highest level of education 3566     <0·001 
x College / University  850 (24%) 236 (30%) 334 (26%) 280 (19%)  
Married/living together 4075 2070 (51%) 385 (48%) 717 (50%) 968 (52%) 0·15 
Employment status before injury 3980     0·05 
x Working  1946 (49%) 427 (52%) 638 (45%) 881 (50%)  
 
Pre-injury health status and medical history 
      
Pre-injury ASA-PS classification 4384     0·56 
x A patient with mild systemic disease  1410 (32%) 268 (32%) 507 (34%) 635 (31%)  
x A patient with severe systemic 
disease 
 462 (11%) 93 (11%) 159 (11%) 210 (10%)  
Previous TBI 4158 402 (9·7%) 120 (15%) 149 (10%) 133 (7·0%) <0·001 
Anticoagulants 4345 298 (6··9%) 46 (5·5%) 133 (8·8 %) 119 (6·0%) <0·001 
Platelet aggregation inhibitors 4345 474 (11%) 85 (10%) 178 (12%) 211 (11%) 0·38 
 
Cause of injury and use of medication  
      
Cause of injury 4388     <0·001 
x Road traffic incident  1682 (38%) 266 (32%) 490 (33%) 926 (45%)  
x Incidental fall  2024 (46%) 424 (51%) 761 (51%) 839 (41%)  
Alcohol involved in the injury (yes or 
suspected) 
4163 1054 (25%) 137 (17%) 384 (27%) 533 (28%) <0·001 
 
x Road traffic incident  262 (26%) 25 (19%) 76 (21%) 161 (33%) <0·001 
x Incidental Fall  533 (54%) 72 (55%) 209 (57%) 252 (51%) <0·001 
       
Clinical presentation 
GCS baseline (median (IQR)) 
   Mild (13-15) 
   Moderate (9-12) 
   Severe (3-8) 
 
4330 
 
15 (10-15) 
2955 (68%) 
389 (9·0%) 
986 (23%) 
 
15 (15-15) 
826 (99%) 
2 (0·2%) 
4 (0·5%) 
 
15 (14-15) 
1409 (93%) 
59 (3·9%) 
21 (1·4%) 
 
9 (4-14) 
720 (36%) 
328 (15%) 
961 (45%) 
 
<0·001 
Pupillary reactivity 
x One pupil unreactive 
x Two pupils unreactive 
4247  
164 (3·9%) 
281 (6·6%) 
 
3 (0·4%) 
16 (2·0%) 
 
27 (1·9%) 
19 (1·3%) 
 
134 (6·6%) 
246 (12%) 
<0·001 
Hypoxia (prehospital/ER phase) 4256 299 (7·0%) 3 (0·4%) 30 (2·1%) 266 (13%) <0·001 
Hypotension (prehospital/ER phase) 4296 297 (6·9%) 4 (0·5%) 26 (1·8%) 267 (13%) <0·001 
Any major extracranial injury (AIS >=3) 4509 1642 (36%) 46 (5·4%) 422 (28%) 1174 (55%) <0·001 
 
CT characteristics  
      
Any intracranial abnormality at local reading 3947 2271 (58%) 55 (7·0%) 639 (47%) 1577 (87%) <0·001 
Any intracranial abnormality at central reading 4037 2434 (60%) 127 (15%) 680 (49%) 1627 (89%) <0·001 
MR characteristics 
Any intracranial abnormality at central reading 
 
Biomarkers
# 
 
504 
 
312 (62%) 
 
32 (26%) 
 
101 (56%) 
  
179 (91%) 
 
<0·001 
NSE (median (IQR), ng/ml)  961 18 (13-27) 13 (11-16·8) 14 (11-18) 23 (15-34) <0·001 
S100B (median (IQR), µg/L) 960 0·18 (0·09-0·42) 0·07 (0·05-0·12) 0·11 (0·06-0·19) 0·30 (0·15-0·59) <0·001 
GFAP (median (IQR), ng/mL) 1010 4·4 (0·8  W 17) 0·3 (0·1  W 1·0) 1·7 (0·6  W 5·1) 11 (3·4  W 31) <0·001 
NF-L (median (IQR), pg/mL) 1010 23 (10  W 60) 8·3 (5·1  W 15) 16 (8  W 30) 40 (18  W 95) <0·001 
t-Tau (median (IQR), pg/mL) 1010 4 (1·7  W 11) 1·2 (0·8  W 2·0) 2·3 (1·3  W 4·5) 7·9 (3·3  W 17) <0·001 
UCHL1 (median (IQR), pg/mL 1009 127 (48  W 381) 35 (20  W 64) 68 (34  W 122) 275 (109  W 597) <0·001 
Laboratory measurements 
Hemoglobin (median (IQR), g/dL) 
 
3846 
 
14 (12  W 15) 
 
14 (13  W 15) 
 
14 (13  W 15) 
 
13 (12  W 14) 
 
<0·001 
Glucose (median (IQR), mmol/L) 3492 6·9 (5·9  W 8·3) 6 (5·3  W 7·1) 6·5 (5·7  W 7·8) 7·3 (6·3  W 8·9) <0·001 
ASA-PS = The American Society of Anesthesiologists (ASA) physical status classification system, GCS = Glasgow Coma Scale; S100B = S100 calcium-binding protein B, NSE = 
Neuron-Specific Enolase, NF-L = Neurofilament Light, GFAP = Glial Fibrillary Acidic Protein, t-Tau = total Tau, UCHL1 = Ubiquitin Carboxy-Terminal Hydrolase L1; 
# 
NSE and S-
100B were measured on the e602 module of a Cobas 8000 analyzer (Roche Diagnostics International Ltd· Rotkreuz, Switzerland) in Pecs, Hungary and NF-L, total Tau, GFAP, 
and UCH-L1 on the Quanterix SIMOA Neurology 4-plex kit (Quanterix, Lexington, MA, USA), at the University of Florida, USA.   
* p-values from ANOVA and chi-square statistics for continuous and categorical characteristics respectively, comparing strata   
Table 2: Care pathways of 4509 patients enrolled in the CENTER-TBI Core study 
Variable N complete N (%) ER (N, %) Admission (N, %) ICU (N, %) p-value*  
Total number of patients  4509 848 1523 2138  
Referral       
Primary referral 4492 3761 (84%) 818 (97%) 1323 (87%) 1620 (76%) <0·001 
x Time to study center (median 
(IQR))  W mins 
4489 65 (45-101) 62 (42-106) 60 (41-96) 50 (72-101)  
Secondary referral 4492 731 (16%) 29 (3·4%) 199 (13%) 503 (24%) <0·001 
x Time to study center (median 
(IQR))  W mins  
4489 295 (211-438) 257 (151-316) 294 (205-428) 300 (217-445)  
 
Diagnostic and surgical interventions  
      
Time from injury to first CT (median (IQR)) 
 W minutes 
3927 110 (71-148) 136 (92-201) 105 (74-158) 105 (78-143) <0·001 
ICP monitor placed 2169 924 (43%) 0 (0) 3 (7%) 921 (44%) <0·001 
GCS <= 8 958 591 (62%) 0 (0) 0 (0) 591 (62%) <0·001 
Intracranial surgery 3686 885 (24%) 1 (2·4%) 64 (4·2%) 820 (39%) <0·001 
Extracranial surgery 3685 735 (20%) 1 (2·4%) 128 (8·4%) 606 (29%) <0·001 
 
Length of stay  
 
3777 
     
From arrival ER to hospital discharge in 
hours and days 
 5·1 (1·3  W 16) 
days 
11 (5·3  W 23) 
hours 
2·5 (1·2  W 5·8) 
days 
17 (7·9  W 32) 
days 
<0·001 
       
Hospital Discharge Destination 4189     <0·001 
 Home  2645 (63%) 804 (99%) 1246 (85%) 595 (31%)  
 Rehab Unit  480 (11%) 0 (0·0%) 59 (4·0%) 421 (22%)  
 Other Hospital  635 (15%) 0 (0·0%) 117 (8·0%) 518 (27%)  
 Nursing Home  49 (1·2%) 1 (0·1%) 2 (0·1%) 46 (2·4%)  
 Other  17 (0·4%) 0 (0·0%) 0 (0%) 17 (0·9%)  
 In-hospital mortality  363 (8·7%) 3 (0·4%) 42 (2·8%) 318 (15%)  
ICP = Intracranial Pressure, GCS = Glasgow Coma Scale  
 
* p-values from ANOVA and chi-square statistics for continuous and categorical characteristics respectively, comparing strata   
Table 3: Outcomes of 4509 patients enrolled in the CENTER-TBI Core study 
 N complete All (N, %) ER (N, %) Admission (N, %) ICU (N, %) p-value* 
Total number of patients  4509 848 1523 2138  
In-hospital mortality 4469 363 (8·1%) 3 (0·4%) 42 (2·8%) 318 (15%) <0·001 
6 months mortality 3804 473 (12%) 9 (1·3%) 70 (5·5%) 394 (21%) <0·001 
6 months GOSE  W N completed 3804 3804 (84%) 694 (82%) 1264 (83%) 1846 (86%)  
6 months GOSE < 8 3804 2419 (64%) 207 (30%) 665 (53%) 1547 (84%) <0·001 
6 months Unfavourable outcome (GOSE < 5) 3804 966 (25%) 31 (4·5%) 140 (11%) 795 (43%) <0·001 
6 months SF-12v2 Mental Component Summary (median (IQR)) 2229 50 (41  W 57) 51 (42  W 57) 51 (42  W 57) 48 (39  W56) <0·001 
6 months SF-12v2 Physical Component Summary (median (IQR))  2229 49 (39  W 55) 51 (41  W 56) 50 (40  W 55) 46 (36 - 53)  <0·001 
6 months Qolibri-OS (median (IQR)) 2233 71 (54-83) 75 (58-91) 75 (58-83) 71 (52-83) <0·001 
6 months SF-12v2 Mental Component Summary <40 (impaired) 
6 months SF-12v2 Physical Component Summary <40 (impaired) 
6 months Qolibri-OS < 52 (impaired) 
2229 
2229 
2233 
522 (23%) 
630 (28%) 
474 (21%) 
100 (21%) 
111 (23%) 
89 (19%) 
181 (21%) 
205 (24%) 
158 (18%) 
241 (27%) 
314 (35%) 
227 (25%) 
0.012 
<0·001 
0·002 
       
 GOSE = Glasgow Outcome Scale Extended, SF-12v2 = Short-Form 12v2, Qolibri-OS = Qolibri-Overall Scale 
* p-values from ANOVA and chi-square statistics for continuous and categorical characteristics respectively 
 
 
Figure 1: Centre participation and recruitment to CENTER-TBI Study. The accrual to ER, Admission, and ICU strata was defined prospectively in the Core 
study, and retrospectively in the Registry.   
 
 Figure 2: Participation per study centre & country in the Center-TBI Core study (n=4509 patients) 
 
The median enrollment by country was 125 (IQR: 50  W 403) and median by site 50 (IQR: 21  W 107). Four countries accounted for 2563/4509 (57%) of 
recruited patients (Netherlands: N=7 centres, n=1,006 patients; the UK: N=9 centres, n=578 patients; Italy: N=8 centres, n=560 patients and Norway: N=3 
centres, n=419 patients). 
  
Figure 3: Age by sex distribution by stratum in the Center-TBI Core study (n=4509 patients). The ER stratum included most females and the ratio of 
females to males increased with older ages in each stratum. 
  
 
ER (n=848) Admission (n=1523) ICU (n=2138) 
  
Figure 4: GCS distribution by stratum, CENTER-TBI- core (n=4,344)  
 
 
 Figure 5: Between-country differences in processes of care for TBI in Europe. [1] performing intracranial surgery, [2] performing extracranial surgery, [3] 
the frequency of secondary referral, [4] frequency of placement of an ICP monitor in GCS<=8. 
 
  
Log odds ratio of intracranial surgery, representing the log odds of 
intracranial surgery per contry compared to the overall average, adjusted 
for IMPACT CT model and stratum 
Log odds ratio of extracrianal surgery, representing the log odds of 
extracranial surgery per contry compared to the overall average, 
adjusted for any major extracranial injury and stratum 
 
 
 
 
 
 
 
  
 
  
Percentage of patients in the ICU stratum (n = 2138) referred from another 
hospital per country  
Percentage of patients with severe TBI (n= 958) with ICP monitor per 
country  
 
Figure 6: Care pathway by stratum in the CENTER-TBI Core study (n=4509 patients). Vertical lines represent the first, second and third transition of care. 
For example, the majority of patients form the ER is discharged home while from the ICU most patients go to the ward. Abbreviations: ICU: Intensive Care 
Unit; ED: Emergency department. HCU: High Care Unit; OR: Operation Room; RU: Rehabilitation Unit; NH: Nursing Home.  
 
Figure 7: GOSE at 6 months by stratum in the Center-TBI Core study (ER n=694; Admission n=1264; ICU n=1846). 
GOSE 1 = dead; GOSE 8 = Upper Good recovery; GOSE categories 2 (Vegetative) and 3 (Lower Severe Disability) are combined as differentiation is not 
possible for assessments performed by postal questionnaire.  
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Table S1: Socio-economic characteristics 
Variable N complete N (%) ER (N, %) Admission (N, %) ICU (N, %) p-value*  
  4509 848 (19%) 1523 (34%) 2138 (47%)  
Years of education (median, IQR) 3212 13 (10  W 16) 13 (11  W 16) 13 (11  W 16)  12 (10  W 15) <0·001 
Highest level of education 3566     <0·001 
x None or primary school  641 (18%) 141 (18%) 224 (17%) 276 (19%)  
x Currently in or with diploma/degree oriented 
program 
 814 (23%) 152 (19%) 324 (25%) 338 (23%)  
x Secondary school  1261 (35%) 258 (33%) 422 (32%) 581 (39%)  
x College / University  850 (24%) 236 (30%) 334 (26%) 280 (19%)  
Marital status 4075      
x Married/living together  2070 (51%) 385 (48%) 717 (50%) 968 (52%) 0·15 
Employment status before injury 3980     0·05 
x Working  1946 (49%) 427 (52%) 638 (45%) 881 (50%)  
x Unable to work/sick leave  127 (3·2%) 23 (2·8%) 46 (3·3%) 58 (3·3%)  
x Retired  1112 (28%) 208 (26%) 438 (31%) 466 (27%)  
x Looking for work   235 (5·9%) 48 (5·9%) 88 (6·2%) 99 (5·7%)  
x Student / schoolgoing  486 (12%) 92 (11%) 174 (12%) 220 (13%)  
x Homemaker   74 (1·9%) 18 (2·2%) 30 (2·1%) 26 (1·5%)  
 
* p-values from ANOVA and chi-square statistics for continuous and categorical characteristics respectively  
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Table S2: Pre-injury health status and medical history  
 N complete All (N, %) ER (N, %) Admission (N, %) ICU (N, %) p-value* 
  4509 848 (19%) 1523 (34%) 2138 (47%)  
Pre-injury ASA-PS classification 4373     0·56 
x A normal healthy patient  2501 (57%) 482 (57%) 836 (56%) 1183 (58%)  
x A patient with mild systemic disease  1410 (32%) 268 (32%) 507 (34%) 635 (31%)  
x A patient with severe systemic disease  462 (11%) 93 (11%) 159 (11%) 210 (10%)  
Medical history      0·21 
x Any  4370 2089 (48%) 413 (49%) 737 (49%) 939 (46%)  
x Cardiovascular disease 4375 1304 (30%) 235 (28%) 492 (33%) 577 (29%)  
x Endocrine disease 4369 583 (13%) 130 (16%) 206 (14%) 247 (12%)  
Diabetic Mellitus  339 (7·8%) 70 (8·3%) 123 (8·1%) 145 (6·8%)  
x Oncologic 4368 285 (6·5%) 63 (7·5%) 110 (7·3%) 112 (5·6%)  
x Pulmonary 4369 443 (10%) 83 (9·9%) 180 (12%) 180 (8·9%)  
x Psychiatric 4352 601 (14%) 127 (15%) 182 (12%) 292 (15%)  
Previous TBI / concussions      <0·001 
x Previous TBI 4158 402 (9·7%) 120 (15%) 149 (10%) 133 (7·0%)  
Anticoagulants 4345 298 (6·9%) 46 (5·5%) 133 (8·8%) 119 (6·0%) 0·001 
Platelet aggregation inhibitors 4345 474 (11%) 85 (10%) 178 (12%) 211 (11%) 0·38 
ASA-PS = The American Society of Anesthesiologists (ASA) physical status classification system, Any Medical History = Cardiovascular disease, Endocrine disease, Oncologic 
disease, Pulmonary disease, Psychiatric disease, TBI = Traumatic Brain Injury. 
* p-values from ANOVA and chi-square statistics for continuous and categorical characteristics respectively  
 
 
 
 
 
Table S3: Cause of injury and intoxications 
 
* p-values from ANOVA and chi-square statistics for continuous and categorical characteristics respectively  
 
 
 N complete All (N, %) ER (N, %) Admission (N, %) ICU (N, %) p-value * 
  4509 848 (19%) 1523 (34%) 2138 (47%)  
Cause of injury 4388     <0·001 
x Road traffic incident  1682 (38%) 266 (32%) 490 (33%) 926 (45%)  
x Incidental fall  2024 (46%) 424 (51%) 761 (51%) 839 (41%)  
x Violence / assault  245 (5·6%) 61 (7·3%) 100 (6·7%) 84 (4·1%)  
x Suicide attempt  48 (1·1%) 1 (0·1%) 3 (0·2%) 44 (2·1%)  
x Other  389 (8·9%) 84 (10%) 145 (9·7%) 160 (7·8%)  
Alcohol involved in the injury (yes or suspected) 4163 1054 (25%) 137 (17%) 384 (27%) 533 (28%) <0·001 
Recreational drugs involved in the injury (yes or 
suspected) 
3938 130 (3·3%) 12 (1·5%) 28 (2·0%) 90 (5·2%) <0·001 
Sedatives or sleeping pills involved in the injury (yes or 
suspected) 
3883 92 (2·4%) 10 (1·2%) 31 (2·2%) 51 (3·0%) 0·020 
 Table S4: Baseline clinical characteristics 
 N complete All (N, %) ER (N, %) Admission (N, %) ICU (N, %) p-value * 
  4509 (100% 848 (19%) 1523 (34%) 2138 (47%)  
GCS baseline (median (IQR)) 
   Mild (13-15) 
   Moderate (9-12) 
   Severe (3-8) 
4330 15 (10-15) 
2955 (68%) 
389 (9·0%) 
986 (23%) 
15 (15-15) 
826 (99%) 
2 (0·2%) 
4 (0·5%) 
15 (14-15) 
1409 (93%) 
59 (3·9%) 
21 (1·4%) 
9 (4-14) 
720 (36%) 
328 (16%) 
961 (48%) 
<0·001 
GCS motor score  4397     <0·001 
   M1-3  828 (18,9%) 4 (0·5%) 20 (1·3%) 804 (38·9%)  
   M4  158 (3·6%) 3 (0·4%) 9 (0·6%) 146 (7·0%)  
   M5  433 (9·8%) 9 (1·1%) 45 (3·0%) 379 (18·3%)  
   M6  2978 (68%) 819 (98%) 1417 (95%) 742 (36%)  
Pupillary reactivity 
   One pupil unreactive 
   Two pupils unreactive 
4247  
164 (3·9%) 
281 (6·6%) 
 
3 (0·4%) 
16 (2·0%) 
 
27 (1·9%) 
19 (1·3%) 
 
134 (6·6%) 
246 (12%) 
<0·001 
LOC (yes or suspected) 3987 2634 (66%) 391 (49%) 883 (64%) 1360 (75%) <0·001 
PTA (yes or suspected)  3092 1483 (48%) 284 (35%) 681 (50%) 518 (58%) <0·001 
Hypoxia (prehospital/ER phase) 4256 299 (7·0%) 3 (0·4%) 30 (2·1%) 266 (13%) <0·001 
Hypotension (prehospital/ER phase) 4296 297 (6·9%) 4 (0·5%) 26 (1·8%) 267 (13%) <0·001 
ISS (median (IQR)) 4453 16 (9-29) 4 (2-8) 10 (9-17) 29 (25-41) <0·001 
Major extracranial injury (AIS >=3)      <0·001 
   Any 4509 1642 (36%) 46 (5·4%) 422 (28%) 1174 (55%)  
   Face  4509 650 (14%) 19 (2·2%) 160 (11%) 471 (22%)  
   Thorax/chest 4509 886 (20%) 8 (0·9%) 136 (8·9%) 742 (35%)  
   Abdomen/pelvis 4509 422 (9·4%) 7 (8·3%) 56 (3·7%) 359 (17%)  
   Extremities 4508 513 (11%) 17 (2·0%) 124 (8·1%) 372 (17%)  
   External 4509 92 (2·0%) 8 (0·9%) 21 (1·4%) 63 (2·9%)  
   Spine 4509 480 (11%) 10 (1·2%) 96 (6·3%) 374 (18%)  
GCS= Glasgow Coma, M = Motor, LOC = Loss of Consciousness, PTA = Post-Traumatic Amnesia, ISS = Injury Severity Score, AIS = Abbreviated Injury Scale (AIS). 
* p-values from ANOVA and chi-square statistics for continuous and categorical characteristics respectively  
Table S5: Characteristics of patients enrolled in the Center-TBI Registry versus Center-TBI Core study.· 
 ER Admission ICU 
 Core Registry Core Registry Core Registry 
 848 (19%) 9839 (43%) 1523 (34%) 8571 (38%) 2138 (47%) 4372 (19%) 
Demographic characteristics       
Age (median, (IQR)) 48 (29  W 64) 50 (29 - 72) 53 (32  W 69) 64 (40 - 81) 49 (29  W 65) 51 (31 - 68) 
Male sex 473 (56%) 5523 (56%)  988 (65%) 5133 (60%)  1561 (73%) 3169 (73%)  
Injury characteristics       
- Road traffic accident 266 (32%)  2191 (24%)  490 (33%) 2077 (25%)  926 (45%) 1636 (39%)  
- Incidental fall 424 (51%)  4851 (52%)  761 (51%) 5237 (64%)  839 (41%) 2039 (49%)  
- Other 146 (17%)  2244 (24%)  248 (17%) 910 (11%)  288 (14%) 496 (12%)  
Baseline clinical characteristics       
GCS baseline (median, (IQR)) 15 (15  W 15) 15 (15  W 15) 15 (14  W 15) 15 (14  W 15) 9 (4  W 14) 12 (5  W 15) 
     Mild (13-15) 826 (99%) 9276 (98%) 1409 (93%) 7735 (94%) 720 (36%) 1466 (49%) 
     Moderate (9  W 12) 2 (0·2%) 96 (10%) 59 (3·9%) 369 (4·5%) 328 (16%) 423 (14%) 
     Severe (3  W 8) 4 (0·5%) 55 (0·6%) 21 (1·4%) 113 (1·4%) 961 (48%) 1093 (37%) 
GCS motor score (median, (IQR)) 6 (6  W 6) 6 (6 - 6) 6 (6  W 6) 6 (6 - 6) 5 (1  W 6) 5 (1 - 6) 
Pupillary reactivity       
- One pupil unreactive 3 (0·4%) 47 (0·5%)  27 (1·9%) 38 (0·5%)  134 (6·6%) 491 (12%)  
- Two pupils unreactive  16 (2%) 81 (0·9%)  19 (1·3%) 126 (1·6%)  246 (12%) 303 (7·3%)  
Major extracranial injury (AIS>=3) 46 (5·4%) 321 (3·3%) 422 (27%) 2410 (28%) 1174 (55%) 2312 (53%) 
CT Characteristics       
Any intracranial abnormality 127 (15%) 498 (5·1%)  682 (49%) 3032 (36%)  1627 (89%) 3509 (81%)  
Key emergency interventions       
Craniotomy for haemtoma/contusion 0 (0%) 6 (0%) 19 (1·2%) 124 (1·5%) 297 (14%) 700 (16%) 
Arrived intubated at ED 2 (0·2%) 50 (0·5%) 15 (1·0%) 53 (0·6%) 929 (44%) 1776 (41%) 
Status on discharge       
- In-hospital mortality 3 (0·4%) 75 (0·8%) 42 (2·8%) 209 (2·5%) 318 (15%) 773 (19%) 
GCS = Glasgow Coma Scale, ICP = Intracranial pressure 
 
 
 
Table S6: CT characteristics from central review 
 N completed All (N, %) ER (N, %) Admission (N, %) ICU (N, %) p-value * 
Total number of patients  4509 848 1523 2138  
Marshall CT classification 4037 4037 835 1382 1820 <0·001 
x Diffuse Injury I (no visible pathology)  1603 (39·7%) 708 (84·8%) 702 (51%) 193 (10.6%)  
x Diffuse Injury II  1558 (38·6%) 116 (13·9%) 569 (41%) 873 (48%)  
x Diffuse Injury III (swelling)  165 (4·1%) 1 (0·1%) 12 (0·9%) 152 (8·4%)  
x Diffuse Injury IV (shift)  32 (0·8%) 0 (0%) 4 (0·3%) 28 (1·5%)  
x V/VI (Evacuated/Non evacuated mass lesion)  679 (16·8%) 10 (1·2%) 94 (6·8%) 573 (31.5%)  
Any intracranial abnormality 
Basal cistern absent / compressed 
4037 
4037 
2434 (60%) 
648 (16%) 
127 (15%) 
9 (1·1%) 
680 (49%) 
60 (4·3%) 
1627 (89%) 
579 (32%) 
<0·001 
<0·001 
Midline shift 4037 465 (12%) 5 (1·0%) 61 (4·4%) 399 (22%) <0·001 
Traumatic subarachnoid haemorrhage (tSAH) 4037 1843 (46%) 81 (10%) 429 (31%) 1333 (73%) <0·001 
Epidural Hematoma 4037 480 (12%) 9 (1·1%) 110 (7·9%) 361 (20%) <0·001 
Acute subdural hematoma 4037 1241 (31%) 35 (4·2%) 310 (22%) 896 (49%) <0·001 
Diffuse Axonal Injury 4037 368 (9·1%) 18 (2·2%) 67 (4·8%) 283 (16%) <0·001 
Contusion 4037 1325 (33%) 41 (4·9%) 265 (19%) 1019 (56%) <0·001 
Any intracranial abnormality: Basal cistern absent / compressed, Midline shift, Traumatic subarachnoid haemorrhage, Epidural Hematoma, Acute subdural hematoma, 
Subacute/chronic subdural hematoma, Mixed density subdural hematoma, Contusion, Mass lesion, Intraventricular haemorrhage, and Traumatic axonal injury.  
* p-values from ANOVA and chi-square statistics for continuous and categorical characteristics respectively 
 
 
 
 
  
 
 
Table S7. Agreement between central and local radiological evaluation of 3,922 admission CT scans.  
 
Agreement Frequencies Concordance Discordance  
  
Kappa (95% CI) Central (N,%) Site (N,%) CR+/SR+ CR-/SR- CR-/SR+ CR+/SR- McNemar (p-value) 
CT+ 0.79 (0.77-0.81) 2358 (60%) 2408(61%) 2184 1340 224 174 0.014 
Epidural hematoma 0.59 (0.55-0.63) 465 (12%) 419 (11%) 282 320 137 183 0.012 
Acute subdural hematoma 0.67 (0.65-0.70) 1200 (31%) 1222 (31%) 936 2436 286 264 0.371 
tSAH 0.67 (0.65-0.70) 1784 (45%) 1500 (38%) 1329 1967 171 455 0.001 
Contusion 0.63 (0.60-0.65) 1278 (33%) 1366 (35%) 994 2272 372 284 0.001 
TAI 0.35 (0.30-0.40) 359 (9%) 378 (10%) 152 3337 226 207 0.387 
MLS 0.75 (0.71-0.78) 456 (12%) 576(15%) 402 3292 174 54 0.001 
Cisternal compression 0.54 (0.50-0.58) 627 (16%) 351 (9%) 290 3234 61 337 0.001 
Kappa values for a positive and negative CT scan (CT+, CT-, see methodology section) and 7 different CT characteristics. Frequencies in which CT characteristics were 
reported by the investigator sites and by the central review are shown, with associated McNemar tests for discordance of paired values. Frequencies of concordance and 
discordance are also shown. CR = Central Review, SR = Site Review. tSAH = Traumatic Subarachnoid Hemorrhage, TAI = Traumatic Axonal Injury, MLS = Midline Shift, CI = 
Confidence Interval. 
 
 
 
 
 
 
 
 
 
 
Table S8: CT and MR agreement for 384 MR early (<3 weeks) scans (derived from central review) 
  
Agreement Frequencies Concordance Discordance  
  
Kappa (95% CI) CT (N,%) MR (N,%) CT+/MR+ CT-/MR- CT+/MR- CT-/MR+ McNemar (p-value) 
Any intracranial abnormality 0·52 (0·44-0·61) 182 (47%) 210 (55%) 142 150 32 60 0·005 
No intracranial abnormality 0·52 (0·44-0·61) 202 (53%) 174 (45%) 150 142 60 32 0·005 
Epidural hematoma 0·64 (0·49-0·79) 34 (9%) 23 (6%) 15 346 15 4 0·022 
Acute subdural hematoma 0·47 (0·36-0·58) 75 (20%) 81 (21%) 45 273 30 36 0·538 
tSAH 0·48 (0·39-0·58) 122 (32%) 90 (23%) 66 238 56 24 0·001 
Contusion 0·65 (0·57-0·74) 84 (22%) 121 (32%) 76 255 8 45 0·001 
TAI 0·15 (0·08-0·22) 21 (5%) 135 (35%) 18 246 3 117 0·001 
MLS 0·28 (0·05-0·50) 19 (5%) 8 (2%) 4 361 15 4 0·022 
Cisternal compression 0·29 (0·05-0·52) 17 (4%) 9 (2%) 4 362 13 5 0·099 
Kappa values for Any intracranial abnormality and 7 different imaging characteristics. Frequencies in which the imaging characteristics were reported on CT and MR are 
shown, with associated McNemar tests for discordance of paired values. Frequencies of concordance and discordance are also shown. CT = Computed Tomography, MR = 
Magnetic Resonance. tSAH = Traumatic Subarachnoid Hemorrhage, TAI = Traumatic Axonal Injury, MLS = Midline Shift, CI = Confidence Interval. 
 
Table S9: Diagnostic and Surgical interventions  
 N completed N (%) ER (N, %) Admission (N, %) ICU (N, %) p-value * 
Total number of patients  4509 848 (19%) 1523 (34%) 2138 (47%)  
ICP monitor placed 2340 924 (43%) 0 (0·0%) 3 (7%) 921 (44%) <0·001 
Intracranial surgery 3686 885 (24%) 1 (2·4%) 64 (4·2%) 820 (39%) <0·001 
Total number of intracranial surgeries  1289 1 65 1224  
x Decompressive craniectomy  204 (16%) 0 (0·0%) 2 (3·1%) 202 (17%)  
x Depressed skull fracture   54 (4·2%) 0 (0·0%) 9 (14%) 45 (3·7%)  
x Acute subdural hematoma   323 (25%) 0 (0·0%) 14 (22%) 309 (25%)  
x Epidural hematoma   134 (10%) 0 (0·0%) 19 (29%) 115 (9·4%)  
x Intracerebral hematoma   32 (2·5%) 0 (0·0%) 1 (1·5%) 31 (2·5%)  
x Ventriculostomy for CSF drainage   162 (13%) 0 (0·0%) 1 (1·5%) 161 (13%)  
x Other   380 (30%) 1 (100%) 19 (29%) 360 (29%)  
Extracranial surgery 3685 735 (20%) 1 (2·4%) 128 (8·4%) 606 (29%) <0·001 
Total number of extracranial surgeries   1305 2 158 1145  
x Maxillofacial  177 (14%) 1 (50%) 36 (23%) 140 (12%)  
x Extremity fracture  457 (35%) 1 (50%) 56 (35%) 400 (35%)  
x Laparotomy  65 (5·0%) 0 (0·0%) 4 (2·5%) 61 (5·3%)  
x Pelvic fracture  64 (4·9%) 0 (0·0%) 5 (3·2%) 59 (5·2%)  
x Spinal stabilization  117 (9·0%) 0 (0·0%) 13 (8·2%) 104 (9·1%)  
x Thoracotomy   13 (1·0%) 0 (0·0%) 2 (1·3%) 11 (1·0%)  
x Other   412 (32%) 0 (0·0%) 42 (27%) 370 (32%)  
CSF = Cerebrospinal Fluid. 
Percentage figures for individual types of surgical procedures are in relation to the total number of extracranial and intracranial surgeries performed (as appropriate in each 
context) 
* p-values from ANOVA and chi-square statistics for continuous and categorical characteristics respectively  
  
Table S10: Glasgow Outcome Scale  ? Extended (GOSE) assessed during follow-up: known (n=3804) versus unknown (n=705)  
Variable GOSE available (N, %) GOSE unknown (N, %) p-value * 
 3804 (84%) 705 (16%)  
Demographic characteristics    
Age (median (IQR)) 51 (30-67) 46 (29-64) 0·023 
x >=65 years 1078 (28%) 176 (25%) 0·056 
Male sex 2530 (67%) 492 (69%) 0·174 
Caucasian 3502 (97%) 626 (95%) 0·013 
 
Socio-economic characteristics 
   
Years of education (median (IQR)) 13 (10-16) 12 (10-15) <0·001 
Highest level of education    
x College / University 757 (25%) 93 (18%) 0·001 
Married/living together 1790 (51%) 280 (48%) 0·0·09 
Employment status before injury    
x Working 1661 (49%) 285 (49%) 0·002 
 
Pre-injury health status and medical history 
   
Pre-injury ASA-PS classification   0·605 
x A patient with mild systemic disease 1203 (22%) 207 (31%)  
x A patient with severe systemic disease 394 (11%) 68 (10%)  
Previous TBI 345 (10%) 57 (8·8%) 0·448 
Anticoagulants 250 (6·8%) 48 (7·3%) 0·726 
Platelet aggregation inhibitors 417 (11%) 57 (8·6%) 0·046 
 
Cause of injury and use of medication  
   
Cause of injury   <0·001 
x Road traffic incident 1454 (39%) 228 (33%)  
x Incidental fall 1715 (46%) 309 (45%)  
Alcohol involved in the injury (yes or suspected) 848 (24%) 206 (32%) <0·001 
 
Baseline clinical characteristics  
   
GCS baseline (median (IQR)) 15 (9-15) 15 (12-15) <0·001 
GCS motor score (median (IQR)) 6 (5-6) 6 (6-6) <0·001 
Pupillary reactivity 
x One pupil unreactive 
x Two pupils unreactive 
 
139 (3·9%) 
257 (7·2%) 
 
25 (3·8%) 
24 (3·6%) 
0·003 
Hypoxia (prehospital/ER phase) 270 (7·5%) 29 (4·3%) 0·003 
Hypotension (prehospital/ER phase) 273 (7·5%) 24 (3·6%) <0·001 
Major extracranial injury (AIS >=3)    
   Spine 427 (11%) 53 (7·5%) 0·003 
ASA-PS = The American Society of Anesthesiologists (ASA) physical status classification system, TBI = Traumatic Brain Injury, GCS = Glasgow Coma Scale, AIS = Abbreviated 
Injury Scale (AIS). 
* p-values from ANOVA and chi-square statistics for continuous and categorical characteristics respectively  
Figure S1: Enrolment in strata by centre. The width of the bars indicates the total number of patients per centre.  
 
 
Figure S2: Cause of Injury by Age Group, CENTER-TBI Core  
 
 
Figure S3 Alcohol use and Cause of Injury, CENTER-TBI Core   
 
*RTI = Road Traffic Incident.  Alcohol Involved in Incidental Fall: 533/1918 (28%), RTI: 262/1528 (17%), 
Violence: 144/226 (64%), Other: 45/359 (13%), Suicide Attempt: 12/40 (30%). 
 
 
 
Figure S4: Biomarkers versus CT Abnormalities by stratum (complete cases analysis, n=898)  
# 
NSE and S-100B were measured on the e602 module of a Cobas 8000 analyzer (Roche Diagnostics International Ltd· Rotkreuz, Switzerland) in Pecs, Hungary and NF-L, total 
Tau, GFAP, and UCH-L1 on the Quanterix SIMOA Neurology 4-plex kit (Quanterix, Lexington, MA, USA), at the University of Florida, USA. Differences between biomarker 
values in patients with any intracranial abnormality versus patients without any intracranial abnormality were tested per stratum with a t-test. The stars above the bars 
indicate significance: ns: p>0·05, *: p<=0·05, **: p<=0·01, ***: p<=0·001, ****: p<=0·0001·.  
 
  
NFL = Neurofilament Light  t-TAU = total TAU  UCHL1 = Ubiquitin Carboxy-Terminal Hydrolase L1 
 
  
NSE = Neuron-Specific Enolase  S100B = S100 calcium-binding protein B GFAP = Glial Fibrillary Acidic Protein 
Figure S5: Biomarkers by GCS levels in the CENTER-TBI Core study (n=898) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
NFL = Neurofilament Light   t-TAU = total TAU 
  
UCHL1 = Ubiquitin Carboxy-Terminal Hydrolase L1 NSE = Neuron-Specific Enolase 
  
 
 
 
 
 
 
 
 
# 
NSE and S-100B were measured on the e602 module of a Cobas 8000 analyzer (Roche Diagnostics International Ltd· Rotkreuz, Switzerland) in Pecs, Hungary and NF-L, total 
Tau, GFAP, and UCH-L1 on the Quanterix SIMOA Neurology 4-plex kit (Quanterix, Lexington, MA, USA), at the University of Florida, USA.   
 
 
 
 
 
 
  
S100B = S100 calcium-binding protein B GFAP = Glial Fibrillary Acidic Protein 
Figure S6: Correlation between glucose, hemoglobin, and six biomarkers (GFAP, NFL, NSE, S100B, UHCL1, t-TAU, n=804). Strong correlations were noted, 
specifically between GFAP, NFL, S100B, UCHL1, and t-TAU (r>0·7)· Only weak correlations were noted between glucose and hemoglobin. 
 
Hgb = Hemoglobin, GFAP = Glial Fibrillary Acidic Protein, NFL = Neurofilament Light, NSE = Neuron-Specific Enolase, S100B = S100 calcium-binding protein B, UCHL1 = 
Ubiquitin Carboxy-Terminal Hydrolase L1,  t-TAU = total TAU· All biomarkers were log transformed.  
